A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

Recruiting now · Phase 1/Phase 2

Conditions studied: Hematological Malignancies, B-cell Non-Hodgkin Lymphoma

In brief

This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.

Key facts

Study ID

NCT07220616

Run by

Daiichi Sankyo

People needed

420

Starts

2026-01-16

Expected to finish

2030-11-30

Last updated by the study team

2026-07-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — New York, New York, United States (enrolling)
• Research Site — Lille, France (enrolling)
• Research Site — Pierre-Bénite, France (enrolling)
• Research Site — Nagoya, Japan (enrolling)
• Research Site — Tokyo, Japan (enrolling)
• Research Site — Tokyo, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.